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A balance between co-inhibitory and co-stimulatory signals in the tumor
microenvironment (TME) is critical to suppress tumor development and progression,
primarily via maintaining effective immunosurveillance. Aberrant expression of immune
checkpoints (ICs), including programmed cell death protein 1 (PD-1), cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and mucin-domain
containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3) and T cell immunoreceptor
with Ig and ITIM domains (TIGIT), can create an immune-subversive environment,
which helps tumor cells to evade immune destruction. Recent studies showed that
epigenetic modifications play critical roles in regulating the expression of ICs and their
ligands in the TME. Reports showed that the promoter regions of genes encoding
ICs/IC ligands can undergo inherent epigenetic alterations, such as DNA methylation
and histone modifications (acetylation and methylation). These epigenetic aberrations
can significantly contribute to the transcriptomic upregulation of ICs and their ligands.
Epigenetic therapeutics, including DNA methyltransferase and histone deacetylase
inhibitors, can be used to revert these epigenetic anomalies acquired during the
progression of disease. These discoveries have established a promising therapeutic
modality utilizing the combination of epigenetic and immunotherapeutic agents to restore
the physiological epigenetic profile and to re-establish potent host immunosurveillance
mechanisms. In this review, we highlight the roles of epigenetic modifications on the
upregulation of ICs, focusing on tumor development, and progression. We discuss
therapeutic approaches of epigenetic modifiers, including clinical trials in various cancer
settings and their impact on current and future anti-cancer therapies.
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INTRODUCTION
Epigenetics involves heritable and long-term changes in gene expression, which are mediated
by various mechanisms, without altering the DNA sequence. In physiological and pathological
settings, epigenetics plays profound, and ubiquitous roles in the regulation of gene transcription
(1, 2). Epigenetic alterations in genes encoding tumor suppressors, suppressive cytokines and
Saleh et al. Epigenetic Modifications in Immune Checkpoints
inhibitory immune checkpoints (ICs) can lead to impaired
activation of anti-tumor immunity, tumor growth, immune
escape and drug resistance, and significantly contribute to cancer
development and progression (3, 4). Genetic and epigenetic
modifications acquired by the tumor microenvironment (TME)
play an indispensable role in tumorigenesis and result in
uncontrolled growth of malignant cells (5). As cancer cells divide,
they acquire genetic and epigenetic alterations giving rise to new
cancer clones with different genetic and epigenetic make-ups,
and inheritable traits favoring growth and survival of malignant
cells (4).
The contribution of ICs to cancer pathogenesis and
progression is well-recognized and has rationalized the
development of monoclonal antibodies that target ICs and their
ligands for cancer therapy (6, 7). Inhibitory ICs and their ligands
are immunomodulatory molecules, and their physiological
expression is crucial to maintain immune hemostasis and
immunosurveillance to avoid potential risks of autoimmunity
(8). Over expression of inhibitory ICs has been recognized as
one of the major contributing factors to cancer development
and progression, as well as autoimmune/chronic inflammatory
diseases. Inhibitory ICs, including cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), programmed cell death protein 1
(PD-1), T cell immunoglobulin and mucin-domain containing-3
(TIM-3), lymphocyte-activation gene 3 (LAG-3) and T cell
immunoreceptor with Ig and ITIM domains (TIGIT), can
negatively influence the activation of antigen-presenting cells
(APCs) and T effector cells (Teffs), and enhance the function of
T regulatory cells (Tregs) and myeloid-derived suppressive cells
(MDSCs) (9).
Immune checkpoints and their ligands are differentially
expressed by immune cells (Table 1). The binding of CTLA-
4 to CD80 and CD86 causes inhibitory signals toward T
cell activation (10). PD-1 is expressed by multiple types of
immune cells, including activated T cells. Upon its interaction
with its ligands, programmed cell death-ligand 1 or 2 (PD-L1
or PD-L2), inhibitory signals are generated to inhibit T cell
activation/proliferation (11, 22, 23). The interaction between
TIM-3 and galectin-9 has also been reported to suppress T
cell function (14). The binding of LAG-3 to its ligand reduces
antigen-specific CD4+ Teff responses and suppresses cytokine
production (24–26). The interaction between TIGIT and its
ligands inhibits Teff activation (19–21).
Despite the success of ICIs in treating various cancer
types, a large proportion of patients show low response rates
Abbreviations: APC, Antigen-presenting cell; BC, breast cancer; CEACAM-
1, carcinoembryonic antigen cell adhesion molecule 1; CRC, colorectal cancer;
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DC, dendritic cell;
DNMT, DNA methyltransferase; HAT, histone aceyltransferase; HDAC, histone
deacetylase; HMGB1, high-mobility group protein B1; IC, Immune checkpoints;
ICI, immune checkpoint inhibitors; LAG-3, Lymphocyte-activation gene 3;
MDSC, myeloid-derived suppressor cells; miRNA, micro RNA; NK, natural
killer cell; PBMC, peripheral blood mononuclear cells; PC, prostate cancer; PD-
1, programmed cell death-1; PD-L1/2, programmed cell death-ligand 1/2; PS,
phosphatidylserine; Teff, T effector cell; TET, ten-eleven translocation; TIGIT,
T cell immunoreceptor with Ig and ITIM domains; TIM-3, T-cell T cell
immunoglobulin and mucin-domain containing-3; TILs, tumor-infiltrating cells;
TME, tumor microenvironment; Treg, T regulatory cell.
TABLE 1 | Expression of immune checkpoints and their ligands.
Immune
checkpoint
Cellular
expression
Ligand Cellular
expression
References
CTLA-4 Tregs and Teffs CD80 and
CD86
APCs (10)
PD-1 Tregs, Teffs, B
cells, NK cells,
mast cells, and
some subsets
PD-L1
PD-L2
Tumor cells,
non-lymphoid and
non-hematopoietic
cells
(11–13)
TIM-3 Tregs, Teffs,
NK cells, and
some subsets of
myeloid cells
Galectin-9
CEACAM1
Soluble
HMGB1
PtdSer
Some myeloid
subsets; Tregs,
Teffs, NK cells, and
some subsets of
myeloid cells;
Released by tumor
cells or activated
DCs: Apoptotic cells
(14–16)
LAG-3 Tregs, Teffs, B
cells, NK cells and
DCs
MHC II APCs (17, 18)
TIGIT Tregs, Teffs and
NK cells
CD112 and
CD155
DCs (19–21)
due to primary or acquired resistance mechanisms. Primary
resistance mechanisms are mainly dependent on the existing
immune response, while acquired resistance mechanisms are
governed by tumor heterogeneity/plasticity, immunosuppressive
cells (including Tregs and MDSCs), T cell exhaustion and
increased expression of inhibitory ICs (6, 8, 9, 27).
The overexpression ICs and their ligands, within the
TME, can be mediated by different forms of epigenetic
alterations, including DNA methylation, histone modifications
and microRNAs (3, 28, 29). Epigenetic modifiers, including DNA
methyltransferase and histone deacetylase inhibitors, can be used
to revert the changes acquired during cancer onset or progression
(30). The use of combined therapies targeting epigenetic
modifications and ICs could serve as a highly promising
therapeutic strategy to restore the physiological epigenetic profile
and to boost anti-tumor immunity. In this review, we focus on
the role of epigenetic modifications regulating IC expression, and
promoting cancer development and progression. We discuss the
different therapeutic approaches of utilizing epigenetic modifiers,
including clinical trials in various cancer settings and their impact
on anti-cancer therapies.
ROLE OF EPIGENETICS IN CANCER
DEVELOPMENT AND PROGRESSION
Epigenetics controls the transcriptional and post-transcriptional
regulations of a vast array of genes, which mediate various
cellular processes and functions ranging from proliferation,
differentiation, invasion, survival, growth, metabolism, and
immune responses (31). The development and progression of
many pathological conditions, including cancer, trauma, and
infectious and autoimmune diseases can be driven by aberrant
epigenetic modifications (1–3, 5). Cancer was initially considered
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as a “genetic disease” due to gene mutations associated with
loss of gene function or gene overexpression; these mutations
were initially thought to be the main driving force behind
disease pathogenies and progression (32). However, there is
emerging evidence implicating a crucial role for epigenetics
in carcinogenesis. During tumorigenesis, the epigenome is
subjected to various alterations such as global changes in histone
modifications, dysregulation in the non-coding RNA networks,
global loss of DNA methylation, and regional hypermethylation
particularly in the promoter regions of tumor suppressor genes
(33). Using whole-genome sequencing, Mack et al. showed
very low mutation rates, and no recurrent somatic single
nucleotide variants were associated with 47 cases of pediatric
brain cancer (hindbrain ependymomas) (34). In addition, the
authors showed that poor prognosis of hindbrain ependymomas
exhibit a CpG island methylation phenotype, which is known to
induce transcriptional silencing of differentiation genes through
trimethylation of lysine 27 on histone H3 (H3K27) (34).
Moreover, genetic alterations in genes encoding enzymes that
regulate DNA methylation and histone modifications are also
responsible for predisposing individuals to cancer (35, 36). For
instance, mutations in DNA methylation enzyme DNMT3a are
found in ∼22% of patients with acute myeloid leukemia (AML)
and T cell lymphoma have been associated with poor disease
outcomes (36–38). Another study showed that mutations in
ten-eleven translocation 2 (TET2) methylcytosine dioxygenase,
which mediates DNA demethylation, are present in ∼15% of
myeloid cancers (39). Mutations in genes encoding proteins that
facilitate histone demethylation on H3K27, such as ubiquitously
transcribed tetratricopeptide repeat, X chromosome (UTX) and
additional sex combs like 1 (ASXL1), have been detected in 11%
of patients with myelodysplastic syndromes and 43% of chronic
myelomonocytic leukemia (40, 41). Furthermore, mutations in
histone lysine acetyltransferases (HATs) and histone deacetylases
(HDACs) have been associated with hematological malignancies
and solid tumors (42).
Global DNA methylation and histone modifications are
closely linked with cancer development and progression. The
level of DNA methylation (hypo or hyper) and levels of histone
methylation or acetylation can vary across different cancer
types. For instance, development of breast cancer has been
associated with global DNA hypermethylation, while prostate
cancer pathology has been linked with DNA hypomethylation
and increased active histone methylation (43). Therefore, these
findings suggest that DNA methylation could occur in a tissue-
specificmanner depending on the TME. Certain patterns of DNA
methylation, hypermethylation or hypomethylation, targeting
specific genes in a particular TME could have a profound
impact on cancer development and/or progression (44, 45).
Based on this and since DNA hypermethylation is associated
with transcriptional silencing (46), it could be anticipated that
development of particular cancer types is driven by DNA
hypermethylation causing reduced expression of genes related
to tumor suppression and activation of anti-tumor immunity
(47). On the other hand, transcriptional activation mediated
by DNA hypomethylation could result in the overexpression
of genes favoring tumor growth, angiogenesis, metastasis and
immunosuppression, leading to the development of cancer types,
which have been linked with DNA hypomethylation (44, 48).
ROLE OF IMMUNE CHECKPOINTS IN
CANCER DEVELOPMENT AND
PROGRESSION
Increased expression of CTLA-4 and PD-1/PD-L1 and their
negative correlations with overall survival (OS) in various cancer
cases have been well-established (49–51). Toor et al. reported
a positive correlation between tumor-node-metastasis (TNM)
staging and increased expression of CTLA-4 in circulating CD4+
T cells of colorectal cancer (CRC) patients (52). Elevated co-
expression of LAG-3 and PD-L1 in tumor tissues from triple
negative breast cancer (TNBC) patients treated with adjuvant
therapy has been associated with poor disease prognosis (53).
Zhang et al. demonstrated that TIM-3 expression, in colorectal
tumor tissues, was positively correlated with TNM staging, lymph
metastasis and shorter OS (54). Furthermore, overexpression of
TIM-3 on tumor-infiltrating cells showed a positive correlation
with poor prognosis and shorter OS in hepatocellular carcinoma
(HCC) patients (55, 56).
More recently, soluble forms of ICs/IC ligands, generated
by alternative splicing and circulating in the plasma of cancer
patients, have been implicated in cancer development and poor
prognosis, and were suggested to serve as prognostic biomarkers.
Simon et al. reported that serum soluble CTLA-4 (sCTLA-4)
in pediatric patients with acute lymphoblastic leukemia can
be used as a prognostic biomarker (57). High levels of sPD-
1 in the plasma of patients with hepatitis B virus (HBV)
were associated with high viral load and increased risk of
hepatocellular carcinoma (HCC) (58). Increased levels of sPD-L1
have also been associated with poor clinical outcomes in various
cancers including HCC, diffuse large B-cell lymphoma, renal cell
carcinoma, and gastric and lung cancer (59–63). Additionally,
poor prognosis and short OS have been linked with elevated
levels of sTIM-3 in HCC patients (64). The mechanisms by
which ICs and IC ligands (membrane-bound or soluble forms)
mediate immunosuppression and promote tumorigenesis have
been reviewed elsewhere (7, 9, 65). Collectively, the interactions
between ICs and their ligands impair APC function, reduce T cell
proliferation and cytokine release, induce T cell apoptosis, and
enhance suppressive activity of Tregs and MDSCs (6, 27).
EPIGENETIC MECHANISMS REGULATING
THE TRANSCRIPTION OF IMMUNE
CHECKPOINTS IN CANCER
The epigenetic machinery is mainly comprised of three
components: DNA methylation, histone modifications (e.g.,
acetylation, methylation, phosphorylation, and ubiquitylation)
and non-coding RNAs/microRNAs (miRNAs) (66). In this
section, we discuss how these mechanisms control the expression
of IC and IC ligand genes in the TME of various cancer types.
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DNA Methylation
DNA methylation is defined as the covalent transfer of a
methyl group to the C-5 position of the cytosine ring of
DNAmediated by DNAmethyltransferases (DNMTs) (67). DNA
methylation patterns are governed by the action of DNMTs:
DNMT1, DNMT3a, and DNMT3b (67, 68). Mechanistically,
transcriptional silencing is mediated by a methylated cytosine by
eliminating components of transcriptional regulation from their
target sites (67).
DNA methylation can be passively lost or actively driven
by TET family of dioxygenases, which catalyze the oxidation
of methylcytosine to hydroxymethylcytosine (69, 70). While
transcriptional silencing is driven by the action of DNMT(s)
leading to DNA methylation, transcriptional activation is caused
by hypomethylation or demethylation facilitated by the action of
TET enzyme(s) (46). Indeed, the imbalance between the activity
of DNMTs and TETs can affect the expression of many genes
favoring transcriptional silencing or activation during many
pathological conditions, including cancer (71). For example, the
upregulation of TET enzymes and downregulation of DNMTs
in the circulation and tumor tissues of breast cancer (BC) and
colorectal cancer (CRC) patients could be associated with DNA
hypomethylation causing the upregulation of ICs/IC ligands
(Figure 1) (28, 29, 72).
Restoring normal patterns of DNA methylation, especially
in genes related to immune modulation and tumorigenesis,
has been recognized as one of the goals for cancer therapy
improvement (as described in Section Epigenetic Modifiers
Targeting DNA Methylation). Aberrant DNA methylation
patterns have been associated with immune evasion in cancer
patients. For instance, Jung et al. reported that genomic
methylation in lung and melanoma patients correlates with the
immune escape signatures, independently of mutation burden
and aneuploidy (73). Additionally, authors found significant
negative correlations between genomic demethylation, and
immunomodulatory-related pathways/immune cell markers
(73), suggesting that demethylation could be responsible for
silencing the transcription of these genes in patients with lung
cancer and melanoma. Interestingly, they reported that global
hypomethylation in these cancer patients correlated with poor
clinical responses following immunotherapy, indicating that
alterations in DNA methylation can be used to predict clinical
benefits of immunotherapies (73). In another study, global DNA
hypomethylation in human melanoma cell lines was associated
with elevated expression of PD-L1, implicating a therapeutic
potential for targeting PD-L1 using DNAmethylation modifying
agents (74).
The role of DNA methylation in regulating the expression
of several ICs/IC ligands in the circulation and tumor tissues
of BC and CRC patients has been addressed previously. Elashi
et al. reported that increased expression of TIM-3, PD-L1,
and TIGIT in the peripheral blood of both BC and CRC
patients (72). DNA methylation has no role in regulating the
expression of TIM-3 in the circulation of BC and CRC patients,
while PD-L1 upregulation was found to be mediated by DNA
hypomethylation (72). Elevated level of TIGIT in the circulation
of CRC patients was mediated by DNA hypomethylation;
FIGURE 1 | Role of DNA methylation in the transcriptional regulation of
immune checkpoint expression. Under physiological conditions, the CpG
islands in the promoter region of immune checkpoints are methylated by
DNMTs, which leads to the transcriptional repression of ICs. However, in the
TME, the activity of DNMTs could be override by the action of TETs causing
TET-mediated active demethylation and favoring IC transcription. TET
inhibitors could be used as a therapeutic agent to block TET-mediated active
demethylation and retain the physiological condition by downregulating the
transcription of genes, including ICs.
however, DNA methylation has no role in regulating the
expression of TIGIT in the circulation of BC patients (72).
Elevated expression of PD-1, CTLA-4, and TIM-3 genes
in breast tumor tissues was found to be mediated by DNA
hypomethylation in the CpG islands of their promoter regions
(28). In the same study, authors found that the promoter
regions of LAG-3 genes were completely hypomethylated in
breast tumor tissues, and paired-normal tissue, suggesting that
DNA methylation has no role in the upregulation of these genes
in BC (28). In another study, it was reported that elevated
expression of CTLA-4 and TIGIT genes in human CRC tumor
tissues is driven by DNA hypomethylation (29). Additionally,
authors demonstrated that DNA methylation plays no role in
the overexpression of PD-1, PD-L1, galectin-9, and TIM-3 in
colorectal tumor tissues (29).
A study by Marwitz et al. demonstrated that elevated
expression of PD-1 and CTLA-4 in tumor tissues of non-
small-cell lung cancer (NSCLC) patients is driven by DNA
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hypomethylation (75). However, increased expression of PD-
L1 in NSCLC tumor tissues was not associated with DNA
methylation (75). In contrast, elevated level of PD-L1 expression
in tumor tissues of head and neck squamous-cell carcinoma
(HNSCC) was a resultant of DNA hypomethylation (76). Goltz
et al. demonstrated that PD-L1 promoter methylation predicts
the survival rate and disease prognosis of various cancer settings,
including CRC, HNSCC and AML (77–79). Another study by
Rover et al. showed that increased expression of CTLA-4, PD-
1, PD-L1, and PD-L2 was associated with DNA hypomethylation
in patients with lower-grade gliomas (80). Altogether, these data
suggest that DNA hypomethylation is responsible for increasing
the expression of ICs/IC ligands in cancers; however, the set of
genes regulated by DNAmethylation differ from one cancer type
to another.
Histone Modifications
Histone Methylation
Histone methylation is another mechanism by which epigenetic
modifications occur to cause transcriptional and post-
transcriptional alterations in many genes, including those
related to cancer development and immune evasion. These
alterations affect chromatin compaction/structure, recruitment
and binding of transcription factors, initiation and elongation
factors with target DNAs, and RNA processing (81). Histone
methylation is a dynamic process which takes place on the
side-chain nitrogen atoms of lysine (K) residues, mainly on H3
followed by H4 (82). It is controlled by the activity of six major
family classes of histone lysine methyltransferase complexes
(KMT1, KMT2, KMT3, KMT4, KMT5, and KMT6). Lysine
residues can be mono- di-, or tri-methylated by the action
of KMTs (83). Lysine methylation can be reversed by lysine
demethylases (KDMs), which also comprised of at least six
families with distinct and overlapping functions (KDM1, KDM2,
KDM3, KDM4, KDM5, and KDM6) (84, 85). The regulation of
histone methylation and demethylation is a complex process
(86); each KMT or KDM family consists of several enzymes
that target a specific lysine residue. Additionally, different
methylation states on lysine residues are controlled by different
family classes of KMT or KDM, and have a different impact on
transcriptional regulation.
Histone methylation on lysine residues appears to be
a more stable mark; its loss on histones H3 and H4
causes transcriptional repression or silencing. Mono-, di- or
trimethylation of lysine 4 in histone H3 (H3K4me1/2/3) and
H3K36me3/me2 correlates with transcriptional activation (87,
88). On the other hand, trimethylation of lysine 9 and 27
in histone H3 (H3K9me3 and H3K27me3) correlates with
repression (Figure 2A) (87, 88). The contribution of histone
methylation to the regulation of IC transcription in breast and
colorectal tumor tissues has been previously demonstrated. We
have shown that upregulation of PD-1, CTLA-4 and LAG-
3 in breast tumor tissues is associated with low enrichment
of repressive histones, H3K9me3 and H3K27me3, in their
promoter regions (Figure 2B) (28). In contrast, the expression
of TIM-3 gene in breast tumor tissues was associated with
low enrichment of H3K27me3 in its promoter region (28).
In another study, increased expression of PD-1 and TIGIT
in colorectal tumor tissues was shown to be associated with
the low abundance of H3K9me3 in their promoter regions
(29). Moreover, transcriptional upregulation of CTLA-4 in
colorectal tumor tissues was found to be driven by the low
abundance of H3K27me3 in its promoter region, while the low
abundance of both H3K9me3 andH3K27me3 repressive histones
was associated with the upregulation of TIM-3 in colorectal
tumor tissues (29). Based on the above findings, it could be
anticipated that targeting the activity of enzymes (KDMs) on
repressive histones, H3K9me3 and H3K27me3, to maintain their
trimethylation can result in the transcriptional repression of
IC/IC ligand, thereby offering a therapeutic strategy for cancer
treatment. The contribution of some of lysine demethylases (such
as KDM3B, KDM4A, and KDM5B) to the development and/or
progression of different cancer types, including breast cancer,
prostate cancer and AML, have been reported, thus rationalizing
the development of drugs targeting the activities of these enzymes
[as reviewed in (89)].
Histone Acetylation
The importance of histone acetylation in regulating gene
transcription and cellular processes, such as immune response,
apoptosis, autophagy, cell cycle arrest, DNA damage repair,
and metabolism, has been shown in cancer (86, 90). It is a
highly reversible process, which involves the catalytic activity
of histone acetyltransferases (HATs) and histone deacetylases
(HDACs) (91). Histone acetylation occurs on lysine residues
at the N-terminus induced by the activity of HATs, resulting
in the removal of the basic charge at unmodified lysine
residues, and leading to active transcription (92, 93). HDACs
and HATs control histone acetylation act in opposite directions
causing an altered structure of the chromatin, and dictate
the accessibility of DNA to transcription factors (sequence-
specific DNA-binding factors) and other elements of the
transcriptional machinery, such as co-activators. Disrupting
the equilibrium of histone acetylation or deacetylation is
also reported to be associated with tumorigenesis and poor
prognosis (94).
HDACs stabilize the nucleosomal DNA-histone interaction
causing transcriptional silencing (Figure 3A), while the action
of HATs mediates transcriptional activation (Figure 3B) (91).
HDACs can be divided into four classes: class I, II, III,
and IV (95). The role of HDACs in cancer epigenetics and
disease development is receiving an increasing attention, and
targeting their activity has recently been postulated as potential
therapeutic strategy for cancer treatment. HDACs repress the
transcription of genes associated with immune responses and
tumor suppression by restricting the accessibility of transcription
factors to their binding sites and inducing a closed chromatin
confirmation (96). Preclinical models of melanoma and lung
adenocarcinoma showed that the expression of PD-L1 and T
cell chemokines can be upregulated by HDAC inhibitors to
enhance the sensitivity of the immune response to anti-PD-1/PD-
L1 therapy and improve clinical outcomes (97, 98). Recently,
Fan et al. reported that upregulated levels of HAT1 is associated
with poor prognosis of pancreatic cancer (99). Using in vitro
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FIGURE 2 | Role of histone methylation in the transcriptional regulation of immune checkpoints. Schematic diagrams simplify the complexity of gene transcription via
histone methylation. Histone methylation depends on the interplay between KMTs (lysine methyltransferases) and KDMs (lysine demethylases). KMTs transfer methyl
group to the histone tails. Under physiological conditions, histone methylation on the 9th and 27th lysine residues of H3 tail (H3K9me3 and H3K27me3, respectively)
leads to transcriptional repression of ICs (A). In tumor conditions, the low abundance of H3K9me3 and H3K27me3 leads to transcriptional activation of ICs such as
PD-1, CTLA-4, LAG-3, and TIM-3. Meanwhile, utilization of KDM inhibitor (KDMi) could be beneficial in restoring the normal levels of ICs (B).
and in vivo models, authors also demonstrated that knockdown
of HAT1 reduced the proliferation of pancreatic tumor cells,
and downregulated PD-L1 expression (99). Furthermore, it was
shown that PD-L1 expression positively correlated with HAT1
expression in pancreatic tumor tissues (99). Altogether, these
findings suggested that HAT1 transcriptionally regulate PD-L1
expression in cancer settings, and implicated that targeting HAT1
activity could be used as a therapeutic approach for cancer
treatment (99) (Figure 3B, i). Alternatively, the use of ICIs
targeting PD-1/PD-L1 axis in patients with acquired resistance
(97, 100) due to aberrant expressions of HAT1 and PD-L1
(99) could be beneficial in maximizing the anti-tumor immune
response, enhancing the sensitivity to ICI, and overcoming
resistance (Figure 3B, ii). Collectively, these findings suggest that
HDACs act opposite to HATs in terms of IC regulation, and that
HDAC inhibition in combination with ICIs could be beneficial
in enhancing the therapeutic efficacy of cancer treatment by
increasing the sensitivity of the host immune response to ICIs.
This particular therapeutic strategy could be favorable for cancer
patients who developed acquired resistance to ICIs.
Given the complexity of epigenetic regulations and knowing
the fact that HATs and HDACs can alter the transcription of
multiple target genes, it is crucial to take this into consideration
during the development of HAT and HDAC inhibitors and the
design of therapeutic protocols. For instance, HDAC inhibitors,
valproic acid (VPA; class I HDAC inhibitor) and trichostatin-
A (TSA; class I and II inhibitor), could induce apoptosis and
alter the acetylation status of p53, on ETS Related Gene (ERG)+
prostate cancer cells (101, 102). In addition, VPA and TSA were
able to repress the transcription of ERG, which its overexpression
has been associated with poor prognosis and unfavorable clinical
outcomes in prostate cancer patients (101).
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FIGURE 3 | Role of histone acetylation in the transcriptional regulation of immune checkpoints. The transcriptional regulation of ICs by means of acetylation relies on
the balance between HATs and HDACs on lysine residues at histone tails. A set of HDACs can keep the heterochromatin structure and downregulate the transcription
of ICs in physiological conditions (A). However, via tumor-acquired mechanisms, HAT activity is dominated resulting in the conversion of heterochromatin (closed
chromatin) to euchromatin (open chromatin) by transferring acetyl molecules to the histone tails, thereby favoring gene transcription. Overexpression of HAT1 can lead
to increased expression of PD-L1 in cancer tissues by enhancing histone acetylation. The use of HAT1 inhibitor (HAT1i) could be useful in restoring the normal
expression of PD-L1- (i) (B). Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 axis could be used in patients with aberrant expression of HAT1 and PD-L1 (ii).
Long Non-coding RNAs and MicroRNAs
Long non-coding RNAs (lncRNAs) are a series of non-
coding RNAs comprised of more than 200 nucleotides.
lncRNAs are pointed to as potential candidates to evaluate
the prognosis, diagnosis, and development of cancers,
even though their capacity of protein-coding is very little
(103). MicroRNAs (miRNAs) are small non-coding RNAs
(19–25 nucleotides long), which complementary pair with
the 3′ untranslated region of target mRNAs, resulting in
the repression of transcription and/or the degradation of
target mRNAs (104). Studies demonstrated that miRNAs
can regulate more than 30% of human genes involved in
many cellular processes, including cell cycle arrest and cell
growth/proliferation/differentiation/apoptosis (105–107).
miRNAs in various cancers can influence the transcriptional
regulation of immunomodulatory genes, including ICs and
their ligands (108). Wei et al. showed that transfection of
human CD4+ T cells with miR-138 abolished the expression
of CTLA-4, PD-1 and FoxP3 expression in glioma mouse
models (109). AnothermiRNAwith tumor-suppressive functions
is miR-28. Li et al. reported that the expression of miR-28
is downregulated ∼30% in exhausted PD-1+ T cells from
melanoma patients (110). Authors reported that miR-28 inhibits
the expression of the TIM-3 and PD-1 in T cells upon the
binding to their respective 3
′
UTRs (110). In ovarian carcinoma,
signaling pathways mediated by the interactions of CTLA-4
with CD80 and PD-1 with PD-L1 are negatively regulated by
mi-R424(322) (111), suggesting the importance of mi-R424 in
the downregulating of CTLA-4 and PD-1 signaling pathways.
In support of this, it was shown that high levels of mi-
R424(322) in tumors are positively correlated with progression-
free survival in patients with ovarian carcinoma (111). More
recently, Richardsen et al. demonstrated that low levels of
miR424-3p in prostate cancer (PC) tissues associated with an
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aggressive phenotype of PC, poor disease prognosis and low
survival rate (112). Authors also reported a negative correlation
between CTLA-4 expression and miR424-3p expression in PC
tissues (112), highlighting the role of miR424-3p in regulating
CTLA-4 expression in PC as it has been reported in other cancer
types (111, 113).
A study by Cortez et al. demonstrated that PD-L1 expression
in NSCLC is negatively regulated by p53 via miR-34, suggesting
that miRNA delivery could serve as a novel therapeutic
approach for lung cancer therapy (114). Studies indicated that
miRNAs can affect the progression of AML by modulating
the expression of target genes such as TIM-3. Based on
bioinformatics, it was predicted that miR-330-5p may silence
the transcription of TIM-3 in the AML cell line, HL-60
(115). Acquired resistance against anti-PD-1 therapy has been
associated with the upregulation of TIM-3 on T cells in lung
cancer and HNSCC patients (116, 117). Another study by
Oweida et al. showed that response to anti-PD-L1 mAb and
radiotherapy was compensated by the increased expression of
TIM-3 on CD8+ T cells and Tregs, associated with tumor
relapse, poor survival rate in a mouse model of head and
neck tumor (118). Collectively, these studies suggest that the
use of ICIs in combination with miRNA therapy to target
alternative ICs, could be beneficial in preventing the development
of acquired resistance in response to anti-PD-1 or anti-PD-
L1 therapies.
In lymphoma, the expression of CTLA-4, PD-1, PD-L1, TIM-
3 and LAG-3 are negatively regulated by miR-146 (119). The
expression of PD-L1 on tumor cells and the suppression of anti-
tumor immunity in human lung cancer are negatively regulated
by miR-200 (120). Another miRNA with tumor suppressive
functions is miR-34a. Its expression is induced by p53, which
in turn suppresses the expression of PD-L1 (120). In line
with this, it was reported that low levels of miR-34a in AML
and NSCLC are positively correlated with the overexpression
of membrane–bound PD-L1 (53, 114). Overexpression of PD-
L1, and low levels of p53 and miR-34a have been associated
with poor clinical outcomes in patients with NSCLC (120).
On the other hand, overexpression of miR-34a can dysregulate
the activation of PD-1/PD-L1 signaling pathway, causing the
reversal of CD8+ T cell exhaustion, and triggering T cell
activation and cytokine expression, such as IFN-γ and TNF-α
(121). In CRC, low levels of miR138-5p, a tumor suppressive
miRNA, positively correlates with advanced disease stages,
lymph node metastasis and poor clinical outcomes (122).
miR138-5p negatively regulates PD-L1 expression in CRC, which
is associated with reduced cell proliferation and cell cycle
progression (122).
Collectively, these findings clearly imply the importance
of miRNAs in regulating the expression of genes related to
tumorigenesis, immune evasion and cancer progression. One
miRNA may have several mRNA targets, and therefore could
influence the function of many genes, pathways and cellular
processes. The overall role of various miRNAs on the regulation
of ICs and their ligands are summarized in Figure 4. The
above findings also suggest the potential therapeutic benefit of
including miRNAs in cancer therapy as it will be discussed below.
FIGURE 4 | miRNA-mediated interruption of interactions between immune
checkpoints and their ligands in the tumor microenvironment. miRNAs which
contribute to the blockade of PD-1/PD-L1 interactions are miR-146, miR-34a,
miR-128, miR-28, miR-146, and miR-424. miR-146 and miR-34a expressed
on tumor cells, and miR-128, miR-28, miR-146, and miR-424 expressed on T
cells. Likewise, miR-424 expressed on APCs, and miR-128, miR-424,
miR-424-3p, and miR-146 expressed on T cells interfere with CD80/CTLA-4
interactions. Furthermore, miR-28, miR-330-5p, and miR-146 expressed on T
cells interfere with TIM-3/galectin 9 interaction. These miRNA-mediated
interruptions could lead to the blockade of downstream pathways, which
ultimately favor anti-tumor immunity.
POTENTIAL THERAPEUTIC
APPLICATIONS OF EPIGENETIC
MODIFIERS FOR CANCER TREATMENT
Studies have shown that cancers exploit epigenetic mechanisms
mainly in two ways: (1) to delineate the normal transcriptional
regulation of gene expression to assist tumor progression;
and (2) to deactivate anti-tumor immune responses, and
regulate oncogenes and tumor suppressor genes. Dysregulated
transcription of co-activators or suppressors of oncogenes/proto-
oncogenes and tumor suppressor genes leads to the development
of various human cancers. Hypomethylation leads to genomic
instability, while hypermethylation may lead to silencing of
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tumor suppressor genes (123). Therefore, the development and
use of epigenetic modifiers aiming to modulate the activity
of enzymes involved in these epigenetic pathways, including
DNMTs, TETs, HATs and HDACs, may offer therapeutic
benefits (96, 124). However, it is important to consider the
complexity of epigenetic regulations and take into consideration
the tumor type, nature of the TME, and all the target
genes that can be altered upon the inhibition of epigenetic
mediators (DNA/histone modifiers) during the development of
epigenetic drugs and the design of therapeutic protocols. The
communication between immune cells and tumor cells via IC/IC
ligand interactions results into immunosuppression and tumor
progression (Figure 5A). Some epigenetic drugs can be used to
enhance anti-tumor immunity by downregulating the expression
of ICs/IC ligands (99) (Figure 5B), while others could be used
in combination with ICIs to improve the sensitivity of the
host response to therapy by upregulating the expression of IC
ligands (97, 100) (Figure 5C). This should be useful during the
assignment of therapeutic protocols for cancer patients.
Epigenetic Modifiers Targeting DNA
Methylation
DNA methylation may lead to silencing of suppressor genes,
such as TP53 and CDKN2A, thereby increasing susceptibility
to cancer onset. Inhibition of DNMTs has been shown to
correlate with increased expression of tumor suppressor genes
and reduction in tumorigenicity (125). Hypomethylating agents,
which inhibit DNMT, target the methylation patterns of
tumor cells to reinstate normal methylation signatures. DNMT
inhibitors (DNMTis), such as 5-azacytidine (AZA/5AC) and
decitabine, have been developed to inhibit and degrade DNMTs,
reverse hypermethylation and promote transcriptional activation
(126). Several signaling pathways such as those related to
double-stranded RNA (ds-RNA) response, type I interferon
response and apoptosis are induced upon the application of
DNMTis. In a preclinical melanoma model, DNMTi treatment
was able to increase the sensitivity to anti-CTLA-4 therapy by
affecting hypermethylated endogenous retrovirus genes (127).
DNMTis, azacytidine and decitabine, have also been shown
effective in increasing PD-L1 and PD-L2 levels in melanoma (97)
(Figure 5C). Animal studies showed that combining azacytidine
or decitabine with anti-CTLA-4 in ovarian cancer and melanoma
is beneficial in improving the immune response to anti-
CTLA-4 and reducing tumor burden (128, 129). Altogether,
these data rationalized the use of DNMTis in combination
with ICIs to maximize the therapeutic efficacy and clinical
outcomes in cancer patients (129). Azacytidine and decitabine
serve as the most commonly used DNMTi in oncology for
the treatment of chronic myelomonocytic leukemia (CMML),
myelodysplastic syndromes (MDS) and AML (130). Treatment
of MDS with decitabine increased the mRNA expression of PD-
1, its ligands (PD-L1 and PD-L2) in addition to CTLA-4 (131),
rationalizing the potential synergy between DNMTi and ICIs
in enhancing the therapeutic efficacy of combined treatment, as
hypomethylation may increase the expression of ICs/IC ligands,
and subsequently sensitize tumor cells to the ICIs (Figure 5C).
Several trials are currently underway to investigate DNMTi use
in treating different solid malignancies (132–134). However,
DNMTi therapies are frequently associated with severe side
effects, no or partial treatment responses and therapy resistance
in a significant patient cohort. Therefore, identifying novel, more
specific targets against DNMTi are currently being explored.
TET-mediated DNA demethylation contributing toward
developmental processes including disease progression and its
dysregulation may lead to tumorigenesis (135). As previously
discussed in Section DNA Methylation, TET-mediated DNA
demethylation could be associated with the overexpression of
IC/IC ligand in the circulation and tumor tissues of patients
with breast and colorectal cancers (28, 29, 72). Therefore, the
inhibition of TET activities can have a therapeutic potential and
could be beneficial in restoring the normal transcriptomic
expression and methylation patterns of IC/IC ligand.
Furthermore, TET mutations have been associated with various
hematological malignancies; however, specific TET protein
inhibitors have not been tested till present in clinical oncology
(124, 136). Nevertheless, upstream targets for TET-associated
pathways have been identified in different malignancies and have
been the focus of numerous preclinical studies. For instance,
mutations in genes encoding isocitrate dehydrogenase 1 and 2
lead to TET1 inactivation in gliomas (137).
Epigenetic Modifiers Targeting Histone
Modifications
HATs modify chromatin histones to exert their effects
of epigenetic modulation of gene transcription, and are
dysregulated in various human diseases including cancers (138).
For instance, HAT1 has been implicated in the transcriptional
upregulation of PD-L1 in pancreatic cancer (99). Additionally,
it has been demonstrated that knockdown of HAT1 reduced
the proliferation of pancreatic tumor cells, and expression
of PD-L1 (99). These findings suggest that targeting HATs
could be beneficial in reducing the expression of IC ligands,
and ultimately could have clinical benefits for cancer patients.
However, in contrast to HDAC inhibitors (HDACis), HAT
inhibitors (HATis) are yet to be explored in preclinical/clinical
trials (139). Significance of HATi is mainly overshadowed by the
well-established HDACi. However, studies have shown that HATi
can be equally potent blockers of tumorigenesis as HDACi (140).
Vorinostat (class I and II) and romidepsin (class I)
are FDA-approved HDACi commonly used to treat several
malignancies. HDACi promote acetylation of histones and
modulate expression of ∼2–10% of cellular genes via effects on
chromatin structure and transcription factor/cofactor binding,
leading to either increase or decrease in expression (141). It
has been shown that the use of vorinostat and panobinostat
(pan-HDACi) is able to increase the expression of PD-L1
in TNBC, and PD-L1 and PD-L2 in melanoma by altering
chromatin compaction on their promoter regions (100, 142)
(Figure 5C).
Other non-canonical effects of HDACis on the regulation
of immune responses are also evident from numerous studies.
Reports have shown that HDACis can inhibit tumor growth
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FIGURE 5 | Effect of epigenetic modifiers on the expression of immune checkpoints and their ligands in the tumor microenvironment. The interaction between
co-inhibitory immune checkpoints on immune cells and their ligands on tumor cells or myeloid cells results in tumor progression, immunosuppression and T cell
exhaustion characterized by increased expression of immune checkpoints, including PD-1, CTLA-4, TIM-3, and LAG-3, and loss of effector functions, such as
cytokine release and cell-mediated cytotoxicity. The interactions between PD-1, TIM-3, CTLA-4, and LAG-3 on T cells with their respective ligands PD-L1/PD-L2,
galectin-9, B7 ligands or MHC II on tumor cells/myeloid cells or APC, generate signals that inhibit T cell activation/proliferation (A). Depending on the tumor
microenvironment and tumor type, the application of epigenetic modifiers can downregulate or upregulate the expression of immune checkpoints and their ligands.
The application of HDAC6 inhibitor (HDAC6i) can downregulate the expression of PD-L1/2, PD-1, TIM-3, and LAG-3, and EZH2 inhibitor (EZH2i) can downregulate
the expression of galectin-9 and TIM-3 (B), indicating the potential benefits of using these modifiers to enhance anti-tumor immune responses and promote
(Continued)
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FIGURE 5 | tumor cell killing. On the other hand, application of DNMT inhibitor (DNMTi; azacytidine or decitabine) can upregulate the expression of PD-L1/2, PD-1
and CTLA-4, and HDAC inhibitor (HDACi; vorinostat; or panobinostat) can upregulate the expression of PD-L1/2 (C), suggesting the potential benefit of combining
epigenetic modifies with immune checkpoint inhibitors, such as anti-CTLA-4, anti-PD-1 or anti-PD-L1, to increase the sensitivity of the host immune response and
promote more potent anti-tumor immunity.
and enhance the host immune response against cancer cells
via the suppression of Tregs and FoxP3 expression (143),
upregulation of NK cell activating ligands, MHCmolecules (class
I and II), enhancement of NK and CD8+ T cell cytotoxicity
and production of pro-inflammatory cytokines (143–145).
Class II HDACi (entinostat) in combination with DNMTi
(azacytidine), anti-CTLA-4 and anti-PD-1 mAbs improved
treatment outcomes, associated with tumor regression and
absence of metastasis in murine models of CT26 colorectal
tumors and 4T1 metastatic breast cancer (146). The number
of tumor-infiltrating FoxP3+ Tregs was significantly reduced
upon treatment with epigenetic modulators, compared to
ICIs; however, the effect of epigenetic modulators on tumor-
infiltrating CD8+ T cell number was similar to that induced
by ICIs alone (146). A study by Orillion et al. demonstrated
that the use of entinostat (class I HDACi) suppressed the
function of MDSC and enhanced the anti-tumor effects of
anti-PD-1 therapy in murine models of lung and renal cell
carcinoma, suggesting a rationale for combining HDACi and
ICIs in clinical trials (147). Other studies showed that using
HDACis in combination with anti-PD-1 therapy enhances
the anti-tumor immune response, reduces tumor burden and
increases survival in murine tumor models (97, 100). Woods
et al. demonstrated that the treatment with HDACi increases
the expression of PD-L1 in murine melanoma mouse model,
thereby enhancing the sensitivity to anti-PD-1 therapy and
overcoming resistance to therapy (97). Similarly, Briere et al.
showed that class I/IV HDACi increased the expression of
PD-L1 in syngeneic tumor models, and demonstrated that
the HDACi in combination with anti-PD-L1 enhanced the
anti-tumor immune response compared to their use as a
monotherapy (148).
Preclinical studies demonstrated that the upregulation of
ICs/IC ligands can be epigenetically modulated. Inhibition of
HDAC activity has been reported to modulate PD-L1 expression
in chronic lymphocytic leukemia (CLL) and melanoma (97,
149). Recently, Knox et al. demonstrated that the use of
HDAC6i significantly reduced the upregulation of PD-L1 and
PD-L2 (Figure 5B) in SM1 murine melanoma model, increased
expression of IFN-γ and IL-2, and improved survival rates
(150). Notably, Kim et al. have recently shown that CG-745,
a class I and HDAC6i, induced IL-2 and IFN-γ expression,
promoted cytotoxic T cell/NK cell proliferation and inhibited
Treg proliferation, which consequently promoted effects of anti-
PD-1 therapy in syngeneic mouse models (151). Furthermore,
Laino et al. showed that HDAC6 inhibition downregulated the
expressions of TIM-3, PD-1, and LAG-3 on expanded T cells
from the circulation of melanoma patients (152), indicating the
potential benefits of blocking HDAC6 activity to alleviate T
cell suppression. Additionally, Bae et al. showed that HDAC6
inhibition reduced the expression of PD-L1 onmultiple myeloma
bone marrow cells and PD-1 expression on CD8+ T cells (153)
(Figure 5B).
The regulation of gene transcription by histone
methylation/demethylation is a complex process, which is
controlled by the activity of different family classes of enzyme
complexes, KMTs (83) and KDMs (84, 85). Different classes of
KTMs and KDMs act on different lysine residues on histone
H3 or H4 and regulate the expression of various target genes.
H3K27me3 is known as a transcriptional repressor for many
genes including those associated with tumor resistance to
therapy (147). Methylation of H3K27me3 is positively regulated
by polycomb repressive complex 2 (PRC2), a member of the
KMT family, and its enzymatic subunit, enhancer of zeste
homolog 2 (EZH2) (147, 154, 155). Together, these data suggest
that targeting EZH2 could interfere with the transcriptional
repression mediated by H3K27me3, and therefore overcome
tumor resistance to therapy and improve disease outcomes.
EZH2 has been implicated in various cancers including
melanomas, ovarian, prostrate, and breast cancers (136, 156).
Increased expression of EZH2 has been associated with the
development of acquired resistance against recombinant IL-2
(rIL2) and anti-CTLA-4 therapies in melanoma mouse model
(154). On the other hand, co-inhibition of EZH2 with rIL-
2/anti-CTLA-4 immunotherapies resulted in the downregulation
of PD-L1 expression in melanoma cells, increased number
of intratumoral PD-1lowTIM-3lowLAG-3lowCD8+ T cells
expressing high levels of IFN-γ and suppression of tumor growth
(154). Using in vitro and in vivo models, EZH2 activity has been
reported to be responsible for the progression of hepatocellular
carcinoma by enhancing the expression of galectin-9, TIM-3
ligand, via the trimethylation of H3K27 (157), suggesting that
inhibition of EZH2 could be useful for targeting galectin-9
and TIM-3 expression (Figure 5B). Collectively, these results
suggest the potential therapeutic benefits of targeting EZH2 in
cancer to downregulate IC/IC ligand expression and enhance
anti-tumor immunity, and rationalized for the development of
histone methylase inhibitors targeting EZH2 in cancer (136),
which are currently under different clinical trials for treating
different malignancies.
Long Non-coding RNAs and microRNAs
as Potential Therapeutic Strategies
for Cancer
A recent study by Ma et al. showed that lncRNA, lnMX1-
215, negatively regulates PD-L1 and galectin-9 in HNCC and
its overexpression significantly reduces tumor cell proliferation
/metastasis in vitro and in vivo (158). Authors proposed lnMX1-
215 as a potential therapeutic target for HNCC by interfering
with PD-1/PD-L1 and TIM-3/galectin-9 signaling pathways and
restoring anti-tumor immunity (158).
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TABLE 2 | Examples of preclinical models and ongoing clinical trials for combination therapies utilizing ICIs and epigenetic modifiers.
Model Therapy Outcome Clinical trial Therapy in cancer patients
Mouse ovarian cancer
model
Decitabine and
anti-CTLA-4
Synergistic reduction in
tumor growth and
prolonged survival rates
(128)
NCT02915523
Phase Ib/II clinical trial in patients with
chemo-resistant epithelial ovarian cancer
Entinostat (class I HDACi), together with
avelumab (anti-PD-L1)
NCT0329217
Phase Ib open label clinical trial in patients
with advanced ovarian cancer or triple
negative breast cancer
Histone lysine methyltransferase (BET)
inhibitor with atezolizumab (anti-PD-L1)
Ex-vivo model for
tumors from metastatic
renal cell carcinoma
(RCC)
EZH2 and DNMT1
inhibitors and
anti-PD-L1
Synergistic reduction in
tumor growth and
prolonged survival rates
(170)
NCT02619253
Phase II/III clinical trial in patients with
advanced renal or urothelial cell carcinoma
Vorinostat (class II HDACi) with
pembrolizumab (anti-PD-1)
NCT02508870
Phase I clinical trial in patients with
hypomethylating agent (HMA)-naïve
myelodysplastic syndromes (MDS)
Azacytidine with atezolizumab (anti-PD-L1)
NCT02397720
Open-Label Phase II trial in patients with
refractory/ relapsed AML and Newly
Diagnosed Older AML
Nivolumab (BMS-936558) in Combination
With 5-Azacytidine (Vidaza) or Nivolumab
With Ipilimumab in combination with
5-Azacytidine
NCT02599649
Phase II trial in patients with
myelodysplastic syndromes (MDS)
Combination of Lirilumab and Nivolumab
With 5-Azacytidine
NCT02530463
Phase II trial in patients with
myelodysplastic syndromes (MDS)
Combination of nivolumab and ipilimumab
with 5-Azacytidine
Mouse melanoma
model
Class II HDACi
(panobinostat) and
anti-PD-1
Slower tumor progression
and prolonged survival
(97)
NCT02453620
Phase I clinical trial in patients with HER2+
breast cancer
Entinostat with
nivolumab (anti-PD-1) and ipilimumab
(anti-CTLA-4)
NCT02395627
Phase II clinical trial in patients with ER+
advanced hormone therapy-resistant
breast cancer
Tamoxifen with vorinostat and
pembrolizumab (anti-PD-1)
Mouse chronic
lymphocytic leukemia
(CLL)
Primary B cell isolated
from CCL patients
and CCL cell lines
HDAC6 inhibitor
(ricolinostat)
Reduction in the
expression of co-inhibitory
receptors on all T cell
subsets, substantially
CD8+ effector and
memory cells (149)
NCT02453620
Phase I clinical trial in patients with solid
tumors; breast adenocarcinoma,
invasive breast carcinoma, metastatic
breast carcinoma, metastatic malignant
solid neoplasm
Entinostat with nivolumab (anti-PD-1) and
ipilimumab (anti-CTLA-4)
NCT02635061
Phase Ib in patients with unresectable
non-small cell lung cancer (NSCLC)
Selective HDAC6 inhibitor (ACY-241) with
nivolumab (anti-PD-1)
Mouse CT26 and 4T1
tumor models
Class I HDACi
(Entinostat),
anti-CTLA-4 and
anti-PD-1
Reduced levels of
MDSCs, enhanced
functions of Teffs (146)
NCT02538510
Single Arm Phase I/II clinical trial in patients
with recurrent unresectable and/or
metastatic squamous cell head and neck
cancer and recurrent unresectable and/or
metastatic salivary gland malignancies
MK-3475 combined with vorinostat and
pembrolizumab (anti-PD-1)
NCT02708680
Phase II clinical trial in patients with
advanced triple negative breast cancer
Atezolizumab (anti-PD-L1) with or without
Entinostat
NCT02638090
Phase I/II trial in patients with immune
therapy naïve and immune therapy
pretreated stage IV NSCLC
Combination of with pembrolizumab and
Vorinostat
Mouse CT26 and 4T1
tumor models
Class I HDACi
(Entinostat), DNMTi,
anti-CTLA-4 and
anti-PD-1
Reduced levels of
MDSCs, enhanced
functions of Teffs (146)
NCT02032810
Phase I in patients with
Unresectable stage III/IV melanoma
Panobinostat and ipilimumab (anti-CTLA-4)
NCT01928576
Phase II clinical trial in patients with
metastatic non-small cell lung cancer
Azacytidine and entinostat with nivolumab
(anti-PD-1)
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miRNAs are aberrantly expressed in many types of cancer and
malignancies; they regulate the expression of tumor suppressor
genes, oncogenes, ICs and immune checkpoint ligands (108).
miRNAs have a great advantage over other non-coding RNAs,
and mRNAs; they are more stable in biopsy specimens and body
fluids, allowing their use as biomarkers (159–161). Moreover,
miRNA expression profiles are tissue-specific, which is helpful in
speeding up the diagnosis of specific cancer types (160, 161). By
upregulating the expression of ICs and IC ligands, miRNAs can
contribute to cancer development/progression and compromise
the anti-tumor immune responses (108, 162). Targeting this
regulatory function of miRNAs can be used to improve clinical
responses and enhance the sensitivity of cancer patients’ response
to immune checkpoint inhibitors (ICIs).
The single blockade of IC commonly results in the
upregulation of alternative ICs, suggesting the emergence of
compensatory mechanisms which ultimately leads to resistance
to ICIs (27, 117, 118, 163). Single miRNA can target multiple
ICs/IC ligand in multiple cell types in the same tumor tissue.
Hence, this will mimic the effect of the treatment with multiple
ICIs and could be used as a therapeutic agent. For instance,
tumor suppressive miRNA, miR-138, can be used to reduce
the expression of PD-1, and CTLA-4, induce tumor cell
apoptosis and impair invasion and tumor metastasis (109, 164,
165). Zhao et al. reported SHNG14/ZEB1/miR-5590-3p positive
feedback loop in diffuse B cell lymphoma (DBCL) is associated
with attenuated CD8+ T cell activation through PD-1/PD-L1
axis, suggesting that targeting SHNG14 holds the promise of
enhancing anti-tumor immunity and restrain tumor progression
(166). Another therapeutic strategy that could be employed in
cancer treatment is targeting the function of tumor promoting
miRNAs using anti-miRNAs (167, 168).
The use of miRNA as a monotherapy is not beneficial andmay
result in adverse immunologic effects, given that each miRNA
can act on multiple target genes, including those encoding
immune modulatory molecules (169). Therefore, small doses of
anti-miRNAs can be used in combination with chemotherapy
or immunotherapies to minimize the risk of adverse effects
(108). In addition, miRNAs could be more beneficial if used
in combination with ICIs. They may increase the sensitivity of
the host immune response to a particular ICI and overcome
tumor acquired resistance. In other words, this combination
therapy would convert non-responder patients into responders.
For instance, Li et al. demonstrated that miR-28 induces T
cell exhaustion by upregulating the expression of PD-1, TIM-
3, and BTLA (110). This potentially suggests that use of miR-
28 in addition to ICIs, especially those targeting PD-1 and/or
TIM-3 could result in beneficial outcomes and enhance anti-
tumor immunity. Studies have shown negative correlations
between miR-138-5p and PD-L1 expression (122), miR-138
and PD1/CTLA-4 expression (109), and miR-424 and PD-
L1 expression (111), suggesting that targeting these miRNAs
increase the expression of ICs. Thus, we could rationalize that
targeting particular miRNAs could be useful in upregulating the
expression of ICs, which increases the sensitivity and efficacy
of ICIs.
CLINICAL TRIALS FOR COMBINED
THERAPEUTIC STRATEGIES OF
EPIGENETIC MODIFIERS AND ICIS
Epigenetic modifiers have the potential to increase the sensitivity
to ICIs and restore more potent anti-tumor immune responses
and enhance the clinical responses in cancer patients. Several
preclinical models have supported the rationale for combining
epigenetic modifiers with ICIs, and implicated the need to
design clinical trials to assess the efficacy of targeting DNA
methylation and HDAC activity, in combination with ICIs, in
different cancers (details of ongoing clinical trials are listed
in Table 2). Results from completed phase II clinical trial of
pembrolizumab (anti-PD-1) in combination with azacytidine in
microsatellite stable (MSS) metastatic colorectal cancer patients
showed that the combined therapy had mild anti-tumor effects
associated with some adverse effects such as anemia, leukopenia
and constipation (171).
CONCLUSIONS AND FUTURE
DIRECTIONS
Epigenetic modifiers have thus seen important advances in recent
years, and currently several are being explored in combination
with established ICIs in various clinical trials (172). The rationale
for these studies is based on the recent success of ICIs in
different cancers, and the unresponsiveness of some cancer
patients to current therapies, which is believed to be associated
with acquired resistance mechanisms mediated by epigenetic
alterations. However, it is noteworthy that several epigenetic
enzymes also contribute to cancer progression via other non-
epigenetic mechanisms, and ultimately combination therapies to
tackle cancer on different fronts with more targeted precision
medicine approaches may provide the most effective anti-cancer
therapy. It is important to note the complexity of epigenetic
regulations while designing epigenetic drugs, and take into
consideration all the target genes, which their transcription can
be regulated by a specific epigenetic drug. In addition, epigenetic
modifiers may have different effects on cancer cells and different
types of immune cells, depending on the target genes (173).
Further investigations are required to assess the clinical efficacy
of using miRNAs in combination with ICIs, and the risk of
adverse effects related to toxicity and potential development
of autoimmunity.
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